A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment

Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Chroma, Katarina, Skrott, Zdenek, Gursky, Jan, Bacovsky, Jaroslav, Moudry, Pavel, Buchtova, Tereza, Mistrik, Martin, Bartek, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897388/
https://www.ncbi.nlm.nih.gov/pubmed/35246527
http://dx.doi.org/10.1038/s41419-022-04651-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897388/
https://www.ncbi.nlm.nih.gov/pubmed/35246527
http://dx.doi.org/10.1038/s41419-022-04651-w

Ejemplares similares